• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults.

作者信息

Lamble Adam J, Schultz Liora M, Nguyen Khanh, Hsieh Emily M, McNerney Kevin, Rouce Rayne H, Gardner Rebecca A, Ghorashian Sara, Shah Nirali N, Maude Shannon L

机构信息

Division of Hematology/Oncology, Seattle Children's Hospital, Seattle, WA.

Division of Pediatric Hematology/Oncology, Stanford University, Stanford, CA.

出版信息

Blood Adv. 2024 Jul 9;8(13):3544-3548. doi: 10.1182/bloodadvances.2024013243.

DOI:10.1182/bloodadvances.2024013243
PMID:38701425
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11261075/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b1e/11261075/b0d19752ab53/BLOODA_ADV-2024-013243-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b1e/11261075/b0d19752ab53/BLOODA_ADV-2024-013243-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b1e/11261075/b0d19752ab53/BLOODA_ADV-2024-013243-gr1.jpg

相似文献

1
Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults.儿童、青少年和年轻成年人接受嵌合抗原受体T细胞（CAR T细胞）治疗后发生T细胞恶性肿瘤的风险。
Blood Adv. 2024 Jul 9;8(13):3544-3548. doi: 10.1182/bloodadvances.2024013243.
2
CAR T-cells for relapsed B-cell ALL in children and young adults.用于治疗儿童和年轻成人复发性B细胞急性淋巴细胞白血病的嵌合抗原受体T细胞
Lancet Oncol. 2018 Mar;19(3):e144. doi: 10.1016/S1470-2045(18)30087-1. Epub 2018 Feb 9.
3
Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.嵌合抗原受体 T 细胞疗法治疗小儿 B-ALL：缩小早期和长期结局之间的差距。
Front Immunol. 2020 Aug 11;11:1985. doi: 10.3389/fimmu.2020.01985. eCollection 2020.
4
Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.嵌合抗原受体 T 细胞治疗中细胞因子释放综合征的特征和危险因素。
Front Immunol. 2021 Feb 23;12:611366. doi: 10.3389/fimmu.2021.611366. eCollection 2021.
5
CAR T-cell expansion: harmful or helpful?嵌合抗原受体T细胞扩增：有害还是有益？
Blood Adv. 2024 Jun 25;8(12):3311-3313. doi: 10.1182/bloodadvances.2024013146.
6
Chimeric Antigen Receptor (CAR) T-Cell Therapy.嵌合抗原受体（CAR）T细胞疗法
JAMA Oncol. 2017 Nov 1;3(11):1595. doi: 10.1001/jamaoncol.2017.2989.
7
CAR T-cells for relapsed B-cell ALL in adults.用于成人复发B细胞急性淋巴细胞白血病的嵌合抗原受体T细胞
Lancet Oncol. 2018 Mar;19(3):e143. doi: 10.1016/S1470-2045(18)30086-X. Epub 2018 Feb 9.
8
The underlying mechanism of chimeric antigen receptor (CAR)-T cell therapy triggering secondary T-cell cancers: Mystery of the Sphinx?嵌合抗原受体 (CAR)-T 细胞治疗引发继发性 T 细胞癌的潜在机制：斯芬克斯之谜？
Cancer Lett. 2024 Aug 10;597:217083. doi: 10.1016/j.canlet.2024.217083. Epub 2024 Jun 24.
9
Intracranial CAR-T cell delivery in glioblastoma patients.脑内 CAR-T 细胞递送至胶质母细胞瘤患者。
Trends Cancer. 2024 Jun;10(6):478-480. doi: 10.1016/j.trecan.2024.05.002. Epub 2024 May 22.
10
Successful Treatment of TCF3-HLF-positive Childhood B-ALL with Chimeric Antigen Receptor T-Cell Therapy.嵌合抗原受体 T 细胞疗法成功治疗 TCF3-HLF 阳性儿童 B-ALL。
Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):386-392. doi: 10.1016/j.clml.2021.01.014. Epub 2021 Jan 28.

引用本文的文献

1
Targeting the roots of myeloid malignancies with T cell receptors.利用T细胞受体靶向髓系恶性肿瘤的根源。
Nat Rev Cancer. 2025 Aug 21. doi: 10.1038/s41568-025-00857-0.
2
Noncanonical and mortality-defining toxicities of CAR T cell therapy.嵌合抗原受体T细胞疗法的非典型及决定死亡率的毒性作用
Nat Med. 2025 Jul 16. doi: 10.1038/s41591-025-03813-5.
3
CAR T cell therapy for children with rheumatic disease: the time is now.用于治疗风湿性疾病患儿的嵌合抗原受体T细胞疗法：时机已至。

本文引用的文献

1
Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System.商业 CAR T 细胞治疗后的第二原发性恶性肿瘤：FDA 不良事件报告系统分析。
Blood. 2024 May 16;143(20):2099-2105. doi: 10.1182/blood.2024024166.
2
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.商业 CAR T 细胞治疗后 T 细胞淋巴瘤和继发原发性恶性肿瘤风险。
Nat Med. 2024 Apr;30(4):984-989. doi: 10.1038/s41591-024-02826-w. Epub 2024 Jan 24.
3
Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy.
Nat Rev Rheumatol. 2025 Jul 2. doi: 10.1038/s41584-025-01272-3.
4
CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future?嵌合抗原受体T细胞疗法用于青少年起病的自身免疫性疾病：前景可期？
Arthritis Res Ther. 2025 May 10;27(1):102. doi: 10.1186/s13075-025-03564-1.
5
CAR T-cells for acute leukemias in children: current status, challenges, and future directions.用于儿童急性白血病的嵌合抗原受体T细胞：现状、挑战及未来方向
Cancer Metastasis Rev. 2025 Apr 23;44(2):47. doi: 10.1007/s10555-025-10261-7.
6
How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives.2025年我们如何采用细胞疗法治疗套细胞淋巴瘤：欧美视角
Bone Marrow Transplant. 2025 Apr 14. doi: 10.1038/s41409-025-02599-x.
7
New player in CAR-T manufacture field: comparison of umbilical cord to peripheral blood strategies.嵌合抗原受体T细胞（CAR-T）制造领域的新参与者：脐带血与外周血策略的比较
Front Immunol. 2025 Mar 21;16:1561174. doi: 10.3389/fimmu.2025.1561174. eCollection 2025.
8
CAR T-cell-associated secondary malignancies challenge current pharmacovigilance concepts.嵌合抗原受体（CAR）T细胞相关的继发性恶性肿瘤对当前的药物警戒概念提出了挑战。
EMBO Mol Med. 2025 Feb;17(2):211-218. doi: 10.1038/s44321-024-00183-2. Epub 2025 Jan 6.
9
Frequency of secondary T-cell lymphoma in chimeric antigen receptor T-cell naïve B-cell lymphoid-lineage cancers is higher than that reported on chimeric antigen receptor T-cell therapy.嵌合抗原受体T细胞初治B细胞淋巴谱系癌症中继发性T细胞淋巴瘤的发生率高于嵌合抗原受体T细胞疗法的报告发生率。
Haematologica. 2025 Mar 1;110(3):768-771. doi: 10.3324/haematol.2024.286002.
10
T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities.接受嵌合抗原受体T细胞（CAR-T）治疗患者中的T细胞淋巴瘤：评估风险和因果关系
Blood. 2024 Dec 12;144(24):2473-2481. doi: 10.1182/blood.2024025828.
嵌合抗原受体T细胞疗法后的继发性癌症
N Engl J Med. 2024 Feb 15;390(7):584-586. doi: 10.1056/NEJMp2400209. Epub 2024 Jan 24.
4
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy.嵌合抗原受体T细胞（CAR-T）疗法后出现继发性恶性肿瘤报告后的未解问题。
Nat Med. 2024 Feb;30(2):338-341. doi: 10.1038/s41591-023-02767-w.
5
Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials.国家基因载体生物库中的复制型逆转录病毒检测（RCR）：60 项临床试验的 1595 份治疗后外周血样本中未发现 RCR。
Mol Ther. 2023 Mar 1;31(3):801-809. doi: 10.1016/j.ymthe.2022.12.006. Epub 2022 Dec 14.
6
Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy.CD19嵌合抗原受体T细胞疗法后后续恶性肿瘤发生率低。
Blood Adv. 2022 Sep 13;6(17):5222-5226. doi: 10.1182/bloodadvances.2022008093.
7
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs.经基因修饰的肠内分泌细胞治疗后的患者发生后续恶性肿瘤的长期随访。
Blood. 2022 Jul 7;140(1):16-24. doi: 10.1182/blood.2022015728.
8
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia.tisagenlecleucel 在儿童和青少年 B 细胞急性淋巴细胞白血病中的安全性汇总分析。
J Immunother Cancer. 2021 Aug;9(8). doi: 10.1136/jitc-2020-002287.
9
Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells.猪源 Bac 修饰的 CD19 嵌合抗原受体 T 细胞输注后产品相关淋巴瘤的研究。
Blood. 2021 Oct 21;138(16):1391-1405. doi: 10.1182/blood.2021010858.
10
The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma.双向增加 B 细胞淋巴瘤和 T 细胞淋巴瘤的风险。
Blood. 2021 Sep 2;138(9):785-789. doi: 10.1182/blood.2020010497.